BOCA RATON, Fla., Nov. 20, 2006 (PRIMEZONE) -- StockMarketNewsAlert.com issues New Trade Alert for BioStem, Inc. (OTCBB:BTEM). According to M. D'Alonzo at First Equity Group Inc., recent news flow from the company has been very positive: "Cryobanks International, Inc., research affiliates at the center of two important cord blood discoveries."
Reports published earlier this month support the increased diversity of the non-controversial umbilical cord blood stem cell. Researchers based at Newcastle University in the United Kingdom have grown an artificial mini-liver from umbilical cord blood stem cells. In a separate study scientists at the Clinical Cell Therapy Lab at the University of Minnesota report successfully differentiating cord blood cells into a type of lung cell called type II alveolar cells.
The Newcastle University finding in late October is considered a critical breakthrough towards creating a completely artificial liver. The importance of this finding for drug development is significant. Currently pharmaceutical companies use animal or human subjects to test treatments for liver diseases and ailments and in many cases the subjects suffer adverse reactions to the test drugs or therapies. Using cord blood stem cell derived mini-livers, pharmaceutical companies can test more applications and drugs without complications or adverse reactions of the testing subjects. The possibility of regenerating a new liver to replace one that has been damaged or destroyed by disease in now on the horizon.
According to the American Liver Foundation, liver disease is among the ten major causes of death in the United States. They report that one in every ten Americans -- 25 million -- are/or have been afflicted with a liver, billary or gallbladder disease. Chronic liver disease accounts for the death of 20,300 Americans each year and currently there are over 17,000 people awaiting a liver transplant.
Another significant finding came from researchers at the Clinical Cell Therapy Lab at the University of Minnesota, Fairview. Working with BioE Inc., St. Paul, MN, they reported successfully differentiating cord blood cells into a type of lung cell called type II alveolar cells. The research team cultured BioE's unique Multi-Line Progenitor Cell(tm) (MLPC(tm)) differentiating it into the lung cells. The ability to grow this cell will greatly aid in the study and development of more effective treatments for various lung diseases such as cystic fibrosis.
More than 35 million Americans have an ongoing lung disease like asthma or chronic obstructive pulmonary disease (COPD). Combining all types of lung disease together it is the number three killer in the United States causing 1 in 7 deaths each year.
"These two discoveries are important additions to the growing list of uses and applications of non-controversial cord blood stem cells, a resource that is virtually limitless. This is further scientific proof that these cells can differentiate to become other than simply blood cells and opens an entirely new chapter in the umbilical cord blood stem cell story," said Cryobanks International President and CEO Dwight Brunoehler.
Newcastle University and University of Minnesota are leaders in the cord blood stem cell research and development field working on a number of studies and projects. In another project headed by BioE Inc., Cryobanks International, Inc., Newcastle and the University of Minnesota are research partners working to develop a new cord blood processing methodology.
"We are honored to be working with these fine institutions and BioE in a separate project that we believe will also have a significant impact on the developing cord blood banking field," continued Mr. Brunoehler.
About Cryobanks:
Cryobanks International, Inc. is a corporation located in Altamonte Springs, Fl., which is to be acquired by BioStem, Inc. (OTCBB:BTEM). The Company is a leader in the collection, processing, and banking of stem cells derived from the umbilical cord immediately after birth. The units of cord blood (CB) are processed and stored by the company for use in unrelated transplants (where the donor is a histocompatible match, but is anonymous and unrelated to the recipient) and for personal storage and use. In recent years, cord blood transplants (CBTs) have become widely recognized as a safe, effective, and in many ways preferable, alternative to bone marrow transplants (BMTs). There is tremendous potential need for CBTs in the United States and worldwide. Cryobanks International, Inc. is well poised to help meet that need, equipped with an inventory of over 9,000 cord blood units. For more information about Cryobanks International, Inc. call 1-800-869-8608 or visit the website at www.cryo-intl.com.
Safe Harbor Statement
This press release contains "forward-looking statements" by BioStem, Inc. These statements relate to future events or financial performance and transactions, and involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements, to be materially different from those contemplated by the forward-looking statements. There can be no assurance that the acquisition described herein will successfully close. We undertake no ongoing obligation, other than that imposed by law, to update these statements. Factors that could affect results, levels of activity, performance or achievements and cause them to materially differ from those contained in the forward-looking statements include the failure to complete the acquisition of Cryobanks, and other factors that can be found in BioStem's filings with the Securities and Exchange Commission, which can be found at www.sec.gov.
About StockMarketNewsAlert.com
StockMarketNewsAlert.com was developed solely for experienced, risk-tolerant investors. Subscribers to StockMarketNewsAlert.com receive daily market commentary reports for select companies trading on various markets. Sophisticated investors are also able to receive for free, select, rare research reports and investor kits on up and coming emerging companies while they are still not widely known.
StockMarketNewsAlert.com's (SMNA) primary focus is promoting awareness among brokers, investors, and others in the investment community who are interested in small- and micro-cap companies. StockMarketNewsAlert.com is dedicated to helping publicly traded companies gain the exposure they need to move forward with the development of their business plans. SMNA's goal is to feature equity investments in micro- or small-capitalization companies that have the potential for long-term appreciation. SMNA provides investors with a complete suite of online interactive financial data and tools that includes quotes, charts, company profiles, news, market commentary and SEC filings, just to name a few. Stockmarketnewsalert.com offers a free financial newsletter. To subscribe or get more information, visit our home page located at www.stockmarketnewsalert.com.
Let Stock Market News Alert help advertise for your company using our effective awareness campaigns. If you're interested in telling your story, we can help. Contact us at info@stockmarketnewsalert.com. SMNA's e-mail alert service is free to those investors who sign up on the SMNA home page. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to Special Situation companies that have the potential of showing increased activity. To subscribe to this free service, visit the Stock Market News Alert home page at http://www.stockmarketnewsalert.com and select the "sign up" button.
Information contained herein is the opinion of stockmarketnewsalert.com and is intended to be used strictly for informational purposes. You should be aware that SMNA attempts to assure itself of the accuracy of the information contained in the analyses it publishes. In this regard, SMNA does, at times, rely on the accuracy of information supplied to it by the companies, which are the subject of SMNA's analyses and/or parties related to those companies. SMNA also relies on the accuracy and integrity of information that is contained in company press releases and reports filed with the SEC. The companies mentioned in this publication have not approved the content or timing of the information being published unless otherwise noted.
SMNA, because it relies on information supplied by various third parties, disclaims any responsibility for the accuracy of such information. Any investor considering making an investment in any security which has been the subject of a SMNA analysis or opinion should, before making any such investment, consult with his/her market professional and/or do his/her own independent research regarding the company which is the subject of an SMNA opinion, recommendation or analysis.
Information regarding companies, which SMNA has an opinion upon, is normally available from many sources including the subject company's filings with the SEC and various press releases issued by the company.
All material herein is information supplied by the company or other sources believed to be reliable. The information contained herein is not guaranteed by First Equity Group, Inc. to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this profile have approved the statements made in this profile. This profile contains forward-looking statements that involve risks and uncertainties. Statements in this press release about the company's future expectations other than historical facts, are "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933, section 21E of the Securities Act of 1934, as that term is defined in the Private Securities Litigation Reform Act of 1995. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements. Such "forward-looking statements" are subject to risks and uncertainties set forth from time to time in the company's SEC reports that could cause results to differ materially from those expressed or implied include, but are not limited to, the results of future tests and the availability of funding for additional research and development. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. First Equity Group is not a licensed broker, broker dealer, market maker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.stockmarketnewsalert.com. First Equity Group has received compensation of forty thousand dollars from a third party. First Equity Group's affiliates, officers, directors, and employees may also have bought or may buy the shares discussed in this profile and may profit in the event those shares rise in value. First Equity Group does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.